Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports success in Merit ES follow-up analysis

Pfizer reports success in Merit ES follow-up analysis

27th July 2009

Pfizer has reported success in its Merit ES analysis at the 96-week follow-up stage.

In a statement, the company said the study showed that treatment-naive HIV patients taking Combivir (zidovudine/lamivudine) with Celsentri/Selzentry (maraviroc) showed comparable virologic suppression to undetectable levels.

Additionally, they demonstrated significantly greater increases in their CD4 T-cell counts during the period when compared to those participants taking efavirenz in combination with zidovudine/lamivudine.

Dr Michael Saag, professor of medicine and director of the Center for Aids Research at the University of Alabama at Birmingham, who presented the findings of the study, said that durable treatments for HIV are “critical”.

“These results further support maraviroc’s durability and safety profile and, therefore, offer the potential to enhance currently available treatment options for treatment-naive HIV patients,” he added.

Earlier this month, the company announced that it has received approval from the European commission, under the EU merger regulation, regarding its pending acquisition of Wyeth.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.